CLINICAL OUTCOMES OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER TREATED WITH EITHER DULOXETINE OR SELECTIVE SEROTONIN REUPTAKE INHIBITORS IN MEXICO

被引：0

作者：

Hong, J. ^{[1
]}

Novick, D. ^{[1
]}

Montgomery, W. ^{[2
]}

Duenas, H. ^{[3
]}

Peng, X. ^{[4
]}

Kadziola, Z. ^{[5
]}

Haro, J. M. ^{[6
]}

机构：

[1] Eli Lilly & Co, Windlesham, Surrey, England

[2] Eli Lilly Australia Pty Ltd, West Ryde, Australia

[3] Eli Lilly Mexico, Mexico City, DF, Mexico

[4] Eli Lilly & Co, Indianapolis, IN 46285 USA

[5] Eli Lilly GmbH, Vienna, Austria

[6] Univ Barcelona, CIBERSAM, Barcelona, Spain

来源：

VALUE IN HEALTH | 2013年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.jval.2013.08.2083

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

下载

页码：A694 / A694

页数：1

共 50 条

[21] Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
Amare, Azmeraw T.
Schubert, Klaus Oliver
Tekola-Ayele, Fasil
Hsu, Yi-Hsiang
Sangkuhl, Katrin
Jenkins, Gregory
Whaley, Ryan M.
Barman, Poulami
Batzler, Anthony
Altman, Russ B.
Arolt, Volker
Brockmoeller, Juergen
Chen, Chia-Hui
Domschke, Katharina
Hall-Flavin, Daniel K.
Hong, Chen-Jee
Illi, Ari
Ji, Yuan
Kampman, Olli
Kinoshita, Toshihiko
Leinonen, Esa
Liou, Ying-Jay
Mushiroda, Taisei
Nonen, Shinpei
Skime, Michelle K.
Wang, Liewei
Kato, Masaki
Liu, Yu-Li
Praphanphoj, Verayuth
Stingl, Julia C.
Bobo, William V.
Tsai, Shih-Jen
Kubo, Michiaki
Klein, Teri E.
Weinshilboum, Richard M.
Biernacka, Joanna M.
Baune, Bernhard T.
FRONTIERS IN PSYCHIATRY, 2018, 9
[22] Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy
Strawn, Jeffrey R.
Mills, Jeffrey A.
Croarkin, Paul E.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2019, 29 (04) : 250 - 255
[23] Study of effects of selective serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder
Safa, Mitra
Sadr, Saeid
Talischi, Firouzeh
Boroujerdi, Fatemeh Ghasem
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY, 2013, 3 (06) : 306 - 313
[24] Effect of Selective Serotonin Reuptake Inhibitors and Immunomodulator on Cytokines Levels: An Alternative Therapy for Patients with Major Depressive Disorder
Eugenia Hernandez, Maria
Mendieta, Danelia
Perez-Tapia, Mayra
Bojalil, Rafael
Estrada-Garcia, Iris
Estrada-Parra, Sergio
Pavon, Lenin
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[25] The effect of selective serotonin reuptake inhibitors in healthy first-degree relatives of patients with major depressive disorder
Knorr, Ulla Benedichte
DANISH MEDICAL JOURNAL, 2012, 59 (04):
[26] Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder
Qin, Sisi
Eugene, Andy R.
Liu, Duan
Zhang, Lingxin
Neavin, Drew
Biernacka, Joanna M.
Yu, Jia
Weinshilboumi, Richard M.
Wang, Liewei
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (03) : 662 - 670
[27] Duloxetine:: A dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder
Kirwin, JL
Gören, JL
PHARMACOTHERAPY, 2005, 25 (03): : 396 - 410
[28] Prevalence of metabolic syndrome in partial responders to selective serotonin reuptake inhibitors with major depressive disorder
Greer, TL
Trivedi, MH
Church, TS
Grannemann, BF
Galper, DI
Sunderajan, P
NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S172 - S173
[29] Selective serotonin reuptake inhibitors in major depressive disorder in children and adolescents (ratio of benefits/risks)
Hjalmarsson, L
Corcos, M
Jeammet, P
ENCEPHALE-REVUE DE PSYCHIATRIE CLINIQUE BIOLOGIQUE ET THERAPEUTIQUE, 2005, 31 (03): : 309 - 316
[30] Salivary cortisol in women with major depressive disorder under selective serotonin reuptake inhibitors therapy
Ewelina Dziurkowska
Marek Wesolowski
Maciej Dziurkowski
Archives of Women's Mental Health, 2013, 16 : 139 - 147

← 1 2 3 4 5 →